Arbutus Biopharma (ABUS) Operating Expenses (2013 - 2026)

Arbutus Biopharma (ABUS) has reported Operating Expenses for 14 consecutive years, with $10.2 million the latest figure, recorded in Q1 2026.

• Quarterly Operating Expenses fell 62.79% year-over-year to $10.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $35.0 million (down 60.7% YoY) and the FY2025 annual result came in at $52.2 million, down 36.67% from the prior year.
• Operating Expenses rose to $10.2 million in Q1 2026 per ABUS's latest filing, from $6.3 million in the prior quarter.
• Over the last five years, Operating Expenses for ABUS reached as high as $28.8 million in Q4 2022 and fell as low as $6.3 million in Q4 2025.
• A 5-year average of $20.3 million and a median of $23.0 million in 2023 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2022 — Operating Expenses soared 35.19% — and 2026, when it sank 62.79%.
• Year by year, Operating Expenses stood at $28.8 million in 2022, then declined by 20.53% to $22.9 million in 2023, then tumbled by 32.26% to $15.5 million in 2024, then sank by 59.11% to $6.3 million in 2025, then jumped by 61.14% to $10.2 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $10.2 million, $6.3 million, and $9.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.